Histogen Inc

Histogen — Conatus Pharmaceuticals — Corporate Update (September 2014)

28 slides from Histogen's corporate update, Sep 2, 2014

  1. Slide 1: Overview/Update, September 2, 2014

    NASDAQ:CNAT Conatus esese Overview/Update Pharmaceuticals eee" September 2, 2014

  2. Slide 2: Forward-looking Statements

    »s° Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective produc

  3. Slide 3: Conatus Pharmaceuticals: Treating the full spectrum of liver disease

    Conatus Pharmaceuticals Treating the full spectrum of liver disease @ Development-stage biotechnology company (NASDAQ:CNAT) e@ Lead Compound: Emricasan (IDN-6556) e First-in-class, orally active pan-caspase protease inhibitor e Activity addresses key drivers of liver disease e@ Mechanism of action i

  4. Slide 4: Attractive Commercial Opportunities

    Attractive Commercial Opportunities Prevalence estimates in US + Big 5 EU @ Acute-on-Chronic Liver @ Chronic Liver Failure @ Non-Alcoholic Fatty Liver Failure (ACLF) (Liver Cirrohsis, LC; and Disease (NAFLD) Portal Hypertension,PH) @ Post Liver Transplant @ Alcoholic Hepatitis HCV Clearance with @ H

  5. Slide 5: MoA and Preclinical Data

    Conatus *%*. MoA and eee Pharmaceuticals ee & Preclinical Data

  6. Slide 6: Caspase Activation Drives Two Pathways

    “ge Caspase Activation Drives Two Pathways oe APOPTOTIC : INFLAMMATORY CASPASE ACTIVATION 7 CASPASE ACTIVATION ACTIVATED CASPASES ACTIVATED CASPASES 21316|7/819| 10 11415 “i 79 Excessive Apoptosis Plus Excessive Inflammation Measured as serum cCK18, Measured as serum ALT Liver Fibrosis Cirrhosis/Fai

  7. Slide 7: Liver Disease: Various Insults — One Target

    »,° Liver Disease: Various Insults — One 7 @ APOPTOTIC INFLAMMATORY CASPASE ACTIVATION CASPASE ACTIVATION ACTIVATED CASPASES ACTIVATED CASPASES 21316|7/819| 10 11415 “i 79 Rapid and sustained reductions in elevated biomarkers of Measured as serum cCK18 apoptosis and inflammation Measured as serum AL

  8. Slide 8: Emricasan Reduces Key Activators of Liver Disease

    “Seee Emricasan Reduces Key Activators of Liver Disease @ Caspase-driven apoptosis releases highly pro-inflammatory microparticles e@ Measured as elevated caspase-cleaved cytokeratin-18 (cCK18) in serum by a commercial laboratory test e Increased inflammation exacerbates insult to liver e Higher cCK

  9. Slide 9: Active in Preclinical Liver Disease Models

    »%, . . mer) . . see Active in Preclinical Liver Disease Models e Emricasan treatment improves liver histology Control @ Reduces hepatic injury and liver fibrosis in a model of cholestatic liver disease oe Control Emricasan @ Inhibits apoptosis, fibrosis and iF inflammation in a model of NASH Contro

  10. Slide 10: Clinical Programs

    Conatus °*:. Clinical Programs Pharmaceuticals &e°e"

  11. Slide 11: Emricasan Clinical Experience to Date

    Emricasan Clinical Experience to Date Studied in 550+ patients e@ Eight Phase 1 trials conducted in the US, EU and Asia e Healthy volunteers and patients with organ impairment e@ Four randomized, placebo-controlled Phase 2 trials conducted in the US and EU @ Included patients with liver diseases due

  12. Slide 12: Emricasan Phase 2 Study Results

    “see Emricasan Phase 2 Study Results ° ‘Change in LT (Mean # SM fom Bastine folowing B10 dosing with Emviasan in subjects with HCV e@ Statistically significant, rapid and sustained reductions in elevated ALT and cCK18 + 4 z e@ Use of ALT in clinical trials: : \eeiaaet a Oe © Elevation at baseline: i

  13. Slide 13: cCK18 Across the Spectrum of Liver Disease

    <° CCK18 Across the Spectrum of Liver Disease Regardless of insult, cCK18 (M30) levels are elevated Patients with chronic HCV Patients with Chronic Liver Disease (mixed etiology) Kronenberger, B ef al. J Viral Hepatitis 2004;12:307-314 M30 (U/L) 800 a o iN & gs & 8 8 8 Joka, D et al. Hepatology 2012

  14. Slide 14: Afflicted Population

    AFFLICTED POPULATION NAFLD @ NASH + Cirrhosis 147 Million’ 1.2 Million? @ Nasu 25 Million’ @ HCV-SUR + Cirrhosis 1.7 Million POLT-HCV-SVR 4 47,500 an ~ | @ NASH + Fibrosis 13 Mion? y 8 Million? @ an 83,000° @ cur 74,0007 Liver Cirrhosis @® Current Emvicasen Trials ACLF Acute-on-Chronic Liver Failure

  15. Slide 15: Emricasan: Key Measures of Activity

    * Emricasan: Keys Measures of Activity Biomarkers + ALT 7 + oCK18 @ rotrsev.sve an fe, Metabolic status iar @ twver cirrhosis + HOMAIR ee Biomarkers @ Biopsy findings + eCk18 + Ishak Fibrosis Score Functional status «Kode Scale + MELD Score + NAS Score + Components of MELD + Child-Pugh Status (O} Po

  16. Slide 16: Clinical Trials in Patients with Cirrhosis

    e Clinical Trials in Patients with Cirrhosis Halting the progression of disease that leads to liver failure @ Three separate trials in patients with liver cirrhosis e Phase 2 trial in liver cirrhosis patients with MELD Score 11-18 (LC) e Phase 2 trial in liver cirrhosis patients with portal hyperten

  17. Slide 17: Liver Cirrhosis Phase 2 Trial: Stabilize or improve organ function

    Need: Stabilize or improve organ function e@ ~80 patients, 3-month double-blind, placebo-controlled, followed by 3-month open-label phase e@ Efficacy variable - primary e@ Change from Baseline in cCK18 e Efficacy variables - secondary e@ Change from Baseline MELD Score and its components e@ Change i

  18. Slide 18: Portal Hypertension (PH) Phase 2

    »ge Portal Hypertension (PH) Phase 2 7 @ Need: Reduce portal hypertension and its consequences @ ~20 subjects, 28-day open-label pilot study e Efficacy variables - primary © Change from Baseline in cCK18 and HVPG 7 7 e Efficacy variables - secondary | Screening atiienkP Ras @ Change from Baseline in

  19. Slide 19: ACLF Phase 2b

    “ege ACLF Phase 2b ° Need: Rescue from potentially catastrophic, exacerbating event e ~60 subjects, 28-day double-blind, placebo-controlled PK/PD study @ Objective 3 ; Emricasan: 5 mg BID e Identify dose for future trials N=15, e Efficacy variables — exploratory Emricasan: 25 mg BID © Change from Ba

  20. Slide 20: POLT-HCV-SVR Phase 2b

    “Se%* POLT-HCV-SVR Phase 2b ° Need: Stabilize/reverse fibrosis and its consequences e@ ~60 subjects, 2-year double-blind, placebo-controlled sponsor-open study e Efficacy variables - primary e@ Change from Baseline in fibrosis using the Ishak Fibrosis Score e Efficacy variables - secondary @ Change

  21. Slide 21: What Does Fibrosis Look Like in Humans?

    What Does Fibrosis Look Like in Humans? HCV and NASH fibrosis are different types ISHAK scoring system is validated for fibrosis due to viral hepatitis but not for fibrosis due to NASH NASH: Centrizonal Fibrosis with focal dense scarring Reason for current discussions regarding fibrosis * ; endpoint

  22. Slide 22: Treating HCV and NASH Fibrosis

    ° Treating HCV and NASH Fibrosis POLT-HCV-SVR study will measure activity against both types + Subset of Post-HCV-SVR liver histology expected to show fibrosis due to both HCV infection and steatosis NASH and HCV Modified from Linda Ferrel, M.D. presentation on ‘Update on Staging of Fibrosis and Cin

  23. Slide 23: Nonalcoholic Steatohepatitis (NASH)

    ‘se Nonalcoholic Steatohepatitis (NASH) An emerging large market opportunity @ Preclinical studies suggest compelling therapeutic potential for emricasan in NASH @ Designing clinical trials to track fibrosis in NASH patients is currently a challenge e Fibrosis progression rate not well characterized

  24. Slide 24: NAFLD/NASH Phase 2: Confirm dose for future studies

    Need: Confirm dose for future studies once regulatory path is defined e ~40 subjects, 28-day double-blind, placebo-controlled @ Objectives e Confirm safety and tolerability in target population e Efficacy variables - primary @ Change from Baseline in ALT e Efficacy variables - secondary e Change fro

  25. Slide 25: Conatus approach to NASH is embedded in clinical studies

    Conatus approach to NASH is embedded in clinical studies NAFLDI NASH POLT- HCV-SVR | PH | Le | ACLF @ NAFLD and NASH e@ Biomarkers (i.e., ALT, CCK18), metabolic panels (i.e., HOMA), Transient elastography, NAFLD Activity Score (NAS) Vv @ NASH with fibrosis e All of the above plus: @ Fibrosis compone

  26. Slide 26: Emricasan Clinical Development

    sage Emricasan Clinical Development . Acute-on-Chronic ‘i ‘ Phase 2b trial results Liver Failure (ALF) expected 4014 Liver Cirrhosis Phase 2 trial interim (Le) results expected 2H15 Post Liver Transplant HCV Clearance with Unresolved Fibrosis (POLT-HCV-SVR) Phase 2b initial interim results expected

  27. Slide 27: Conatus Pharmaceuticals: Treating the full spectrum of liver disease

    Conatus Pharmaceuticals Treating the full spectrum of liver disease Emricasan: first-in-class, oral pan-caspase protease inhibitor e Addressing the key underlying drivers of liver disease e@ Mechanism of action indifferent to insult Viral infection, alcohol, obesity, and autoimmune diseases all incr

  28. Slide 28: Publications / Investor Relations

    Publications errr Investor Relations edte Contact Us For More Information www.conatuspharma.com Conatus Pharmaceuticals

Conatus Pharmaceuticals — Corporate Update (September 2014) on 6ix